Skip to main content
main-content
Top

01-11-2016 | Oncology | News | Article

News in brief

Tivozanib promising in metastatic, recurrent soft-tissue sarcoma

medwireNews: The oral tyrosine kinase inhibitor tivozanib shows anti-tumor activity and is well tolerated in patients with advanced soft-tissue sarcoma.

The phase II study, reported in the Annals of Oncology, enrolled 58 patients who had received 1–4 prior treatments for metastatic or recurrent disease.

Treatment with tivozanib 1.5 mg/day – as a 3 weeks on, 1 week off schedule – led to a progression-free survival (PFS) rate at 16 weeks of 36.4% and a median PFS duration of 3.5 months, which the researchers describe as “promising”.

Two patients achieved a partial response, while just over half (54.5%) had stable disease, report Mark Agulnik (Northwestern University, Chicago, Illinois, USA) and team.

Forty-three percent of participants experienced a grade 3 side effect, with hypertension, decreased ejection fraction and fatigue the most common grade 3 or 4 events related to treatment. And four patients discontinued treatment as a result of toxicity.

These results support further research to evaluate the clinical efficacy of the anti-vascular endothelial growth factor receptor 1–3 agent in patients with soft-tissue sarcoma, the authors say.

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016